针对非正规激活途径的p38α自酸化抑制剂的表征
Lorena González1, Lucía Díaz2, Joan Pous1
1Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028, Barcelona, Spain.
确定了新的非正规的p38α抑制剂 (NC-p38i),以向p38α通路的特定功能. 这些化合物通过选择性调节疾病中的p38α信号提供了一个新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 对于细胞应激反应而言,p38α激酶至关重要.
- 对p38α信号的失调与炎症,免疫系统疾病和癌症有关.
- 之前的p38α抑制剂在临床上取得了有限的成功,因此需要采用替代方法.
研究的目的:
- 为了识别针对p38α信号的新型化合物.
- 探索p38α调制的替代机制.
- 开发针对p38α相关疾病的向治疗方法.
主要方法:
- 在非正规的p38α抑制剂 (NC-p38i) 的体鉴定.
- 生物化学测试以评估抑制剂活性.
- 结构分析以了解抑制机制.
主要成果:
- 成功确定了NC-p38i化合物.
- NC-p38i有效地抑制了p38α的自酸化.
- NC-p38i显示了对正规p38α通路活性的弱抑制.
结论:
- 可以利用p38α的结构可塑性进行治疗开发.
- NC-p38i代表了选择性p38α通路调节的有希望的策略.
- 针对特定的p38α功能为各种疾病提供了新的治疗机会.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
相关概念视频
The JAK-STAT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
The Intrinsic Apoptotic Pathway
